ACH 4471

Drug Profile

ACH 4471

Alternative Names: ACH-0144471; ACH4471

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Haemolytic uraemic syndrome

Most Recent Events

  • 06 Nov 2017 ACH 4471 receives Orphan Drug status for Paroxysmal nocturnal haemoglobinuria in USA
  • 06 Nov 2017 The European Medicines Agency Committee for Orphan Medicinal Products issues a positive opinion for orphan status in Paroxysmal nocturnal haemoglobinuria
  • 01 Nov 2017 Achillion plans a phase II trial for Paroxysmal nocturnal haemoglobinuria (Combination therapy) in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top